Solifenacin (solifenacin succinate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Solifenacin succinate, an antimuscarinic agent, is a genitourinary antispasmodic.
Solifenacin succinate is a potent and selective antimuscarinic agent. The drug inhibits contraction of the detrusor muscle of the bladder, resulting in decreased bladder activity. Solifenacin demonstrated binding specificity for muscarinic M3 receptors in vitro and functional selectivity for urinary bladder over secretory (e.g., salivary) glands.
Following oral administration in healthy individuals, peak plasma concentrations of solifenacin are achieved within 3-8 hours. The absolute bioavailability is approximately 90%, and plasma concentrations are proportional to the dose administered. Food does not affect the pharmacokinetics of solifenacin.
Solifenacin is highly distributed to tissues outside the CNS; the drug is approximately 98% bound to plasma proteins (mainly to alpha1-acid glycoprotein). Solifenacin is extensively metabolized in the liver, mainly via the cytochrome P-450 (CYP) 3A4 isoenzyme. The elimination half-life of the drug following chronic administration is approximately 45-68 hours.
Following a single oral dose of radiolabeled solifenacin succinate, approximately 69 or 23% of the dose was excreted in urine or feces, respectively, over 26 days; unchanged drug accounted for less than 15% of the recovered radioactivity in urine.
USES: Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom.
This medication belongs to the class of drugs known as antispasmodics.
Generic name: solifenacin succinate
Pronunciation: (SOE-li-FEN-a-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Solifenacin
Indications
The following indications are listed for Solifenacin:
- Bladder Hyperactivity
- Increased Urinary Frequency
- Urinary Urge Incontinence
- Urinary Urgency
Also known as: Detrusor Overactivity, Hypertonic Bladder, Hypertonicity Of Bladder, Low Compliance Of Bladder, Overactive Detrusor, Urge Incontinence, Urge Urinary Incontinence, Urinary Frequency.
Dosing
Dosage of solifenacin succinate is expressed in terms of the salt.
For the management of overactive bladder, the recommended dosage of solifenacin succinate in adults is 5 mg once daily. If well tolerated, dosage may be increased to 10 mg once daily.
Solifenacin succinate is administered orally once daily without regard to meals. Solifenacin succinate tablets should be administered with liquids and swallowed whole.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Urinary retention, gastric retention, or uncontrolled angle-closure glaucoma.
Known hypersensitivity to solifenacin succinate or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects reported in 5% or more of patients receiving solifenacin and at an incidence higher than that reported with placebo included dry mouth and constipation.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of solifenacin have not been established in children younger than 18 years of age.
Category C. (See Users Guide.)
Distributed into milk in mice; not known whether solifenacin is distributed into human milk. Discontinue nursing or the drug.
Prolonged half-life and increased plasma concentrations have been reported in geriatric patients. However, no substantial differences in safety and efficacy relative to younger adults have been observed.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.